title: Switching from donepezil or rivastigmine to galantamine in clinical practice.
authors.forename: Keith
authors.initials: K
authors.lastname: Edwards
authors.forename: Judy
authors.initials: J
authors.lastname: Therriault O'connor
authors.forename: Carol
authors.initials: C
authors.lastname: Gorman
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D000077265:Donepezil; D005702:Galantamine / Q000008:administration & dosage*; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D018697:Nootropic Agents / Q000008:administration & dosage*; D048448:Phenylcarbamates / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D000068836:Rivastigmine
chemical_list: D007189:Indans; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine